Virinder Nohria

UCB Pharma, Inc. provides research, development & commercialisation of pharmeceutical and biotechnology products. Its products are Keppra, Xyzal, Atarax, Lortab, Dipentum, and Tussionex. UCB Pharma develops small and large molecule treatments for a variety of diseases and ailemts. The company was founded by Emmanuel Janssen in 1928 and is headquartered in Smyrna, GA.

DevCo Pharmaceuticals Ltd specializes in marketing, licensing, and development of prescription medicines. The private company is based in London, UK.

DFW Capital Partners (DFW Capital Partners) is a private equity firm founded in 1983 by Donald F. DeMuth. The firm is headquartered in Teaneck, New Jersey.

HZNP USA LLC acquires, develops, markets and distributes specialty pharmaceutical products. The firm offers Actimmune, which is a bioengineered form of interferon gamma-1b, a protein that acts as a biologic response modifier through stimulation of the human immune system. Its Actimmune product is used for reducing the frequency and severity of serious infections related to chronic granulomatous diseases, and for delaying time to disease progression in patients with severe malignant osteopetrosis. The company was founded in 2011 by Balaji K. Venkataraman and Virinder Nohria and is headquartered in Lake Forest, FL.

Promentis Pharmaceuticals, Inc. engages in the develop of novel compounds for the treatment of schizophrenia and other central nervous system disorders. The firm's drug development efforts are focused on the neurotransmitter glutamate and its critical role in the pathophysiology of schizophrenia and other disesses. It discovers, develops and markets new drugs for the treatment of important human diseases, focusing initially on developing a new antipsychotic drug to treat schizophrenia. The company was founded by David A. Baker and John Mantsch in 2007 and is headquartered in Milwaukee, WI.

Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

Xcel Pharmaceuticals, Inc. used to manufactures pharmaceutical products. The company was engaged in prescription products that treat disorders of the central nervous system. Its portfolio included four products, two that were used to treat epilepsy and two that were used to treat migraine. The company was founded in 2001 by Cam L. Garner and was headquartered in San Diego, CA